Mortality associated with cardiovascular disease in patients with COVID-19

Alberto Cordero a,b,∗, Carlos Santos García-Gallego c,d, Vicente Bertomeu-González a,b, Lorenzo Fácila e, Moisés Rodríguez-Mañero b,f, David Escribano a, José M. Castellano g,h,i, Pilar Zuazola a, Julio Núñez b,j,k, Juan J. Badimón c,d, José Ramón González-Juanatey b,f

a Departamento de Cardiología, Hospital Universitario San Juan de Alicante, Alicante, Spain
b Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain
c Mount Sinai School of Medicine, New York, United States
d Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, United States
e Departamento de Cardiología, Hospital General Universitario de Valencia, Spain
f Departamento de Cardiología, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain
g Departamento de Cardiología, Centro Integral de Enfermedades Cardiovasculares (CIEC), Hospital Universitario HM Montepríncipe, Madrid, Spain
h Centro Nacional de Investigaciones Cardiovasculares (CNIC), Instituto de Salud Carlos III, Madrid, Spain
i Facultad de Medicina, Universidad CEU San Pablo, Madrid, Spain
j Departamento de Cardiología, Hospital Clínico Universitario de Valencia, Valencia, Spain
k Instituto de Investigación Sanitaria (INCLIVA), Hospital Clínico Universitario de Valencia, Spain

ARTICLE INFO

Article history:
Received 3 September 2020
Accepted 22 October 2020
Available online 26 October 2020

Keywords:
COVID-19
Coronavirus
Cardiovascular disease
Mortality

INTRODUCTION AND OBJECTIVES: Cardiovascular disease (CVD) has been outlined as a possible risk factor for poorer outcomes in patients with COVID-19.

Methods: A meta-analysis was performed with currently available studies that report the prevalence of CVD in survivors vs non-survivors in patients with COVID-19 using reports available at 16 July 2020. Analyses were performed by a random effects model and sensitivity analyses were performed for the identification of potential sources of heterogeneity or to assess the small-study effects.

Results: A total of 307,596 patients from 16 reports were included and 46,321 (15.1%) had CVD. Globally, mortality rate was 8.2% (20,534 patients) and mortality rates were higher in hospital registries (48.7%) compared to national reports (23.1%). A total of 11,213 (24.2%) patients with CVD died and mortality rates were also higher in hospital registries (48.7%) compared to national reports (23.1%). CVD was associated to a 4-fold higher risk of mortality (OR, 4.33; 95%CI, 3.16–5.94). Data from 28,048 patients with diabetes was available. Diabetes was associated to higher mortality risk (OR, 2.41; 95%CI, 1.79–3.26; P < .001). From 40,173 subjects with hypertension it was concluded that hypertension was also a risk factor for higher mortality (OR, 2.60; 95%CI, 2.10–3.21; P < .001).

Abbreviation: CVD: cardiovascular disease.
∗ Corresponding author.
E-mail address: acorderofort@gmail.com (A. Cordero).
https://doi.org/10.1016/j.rccl.2020.10.005
2605-1532/© 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.
Conclusions: Patients with CVD and COVID-19 have a 4-fold higher risk of death. Diabetes and hypertension are also associated with higher mortality risk.

© 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Mortalidad asociada a las enfermedades cardiovasculares en pacientes con COVID-19

RESUMEN

Introducción y objetivos: Las enfermedades cardiovasculares (ECV) se han identificado como un factor de riesgo de mal pronóstico en los pacientes con COVID-19.

Métodos: Se realizó un metaanálisis de estudios actualmente disponibles con la prevalencia de ECV en supervivientes frente a no supervivientes en pacientes con COVID-19 hasta el 16 de julio de 2020. Los análisis se realizaron mediante un modelo de efectos aleatorios y sensibilidad. Se realizaron análisis para identificar posibles fuentes de heterogeneidad o evaluar los efectos de los estudios pequeños.

Resultados: Se incluyó a 307.596 pacientes de 16 estudios, de los que 46.321 (15,1%) tenían ECV. La tasa de mortalidad fue del 8,2% (20.534 pacientes) y fue superior en los registros hospitalarios (48,7%) en comparación con los informes nacionales (23,1%). Un total de 11.213 (24,2%) pacientes con ECV fallecieron y las tasas de mortalidad también fueron más altas en los registros hospitalarios (48,7%) en comparación con los informes nacionales (23,1%). La ECV se asoció con un riesgo de mortalidad 4 veces mayor (OR: 4,33; IC 95%: 3,16-5,54). Se disponía de datos de 28.048 pacientes con diabetes que también se asoció a un mayor riesgo de mortalidad (OR: 2,41; IC 95%: 1,79-3,26; p < 0,001). De 40.173 pacientes con hipertensión, también se concluyó que era un factor de riesgo de mayor mortalidad (OR: 2,60; IC 95%: 2,10-3,21; p < 0,001).

Conclusiones: Los pacientes con ECV y COVID-19 tienen un riesgo 4 veces mayor de muerte. La diabetes y la hipertensión arterial también son factores de mayor riesgo en los pacientes con COVID-19.

© 2020 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

1. Introduction

After the outbreak of the novel coronavirus in China, the coronavirus disease 2019 (COVID-19), and its worldwide spread, the World Health Organization (WHO) declared its incidence as pandemic in February 2020. The lack of reliable information lead to early and worthy reports of clinical features and mortality rates. Most initial clinical data came from hospital registries and, therefore, reflected the in-hospital course and mortality of patients with COVID-19 infection. By the end of April, the pandemic had widely affected Europe and more than 50,000 patients had died.

Although most patients with COVID-19 infection develop mild symptoms, a relevant percentage that can be from 15 to 20%, develop pulmonary insufficiency and systemic symptoms that require hospitalization or intensive care treatments. To elucidate what are the risk factors for severe illness or death remains a clinical challenge. Patients with cardiovascular disease (CVD) are at increased risk of infections and have higher mortality rates for infectious diseases. Comorbidities, and specially age or CVD, have been outlined as a risk factor for poorer outcomes in COVID-19 patients from the first reports and also in European cohorts. In collaboration with the National Health Commission of China a risk score to predict severe COVID-19 disease that includes CVD as one of the qualifying comorbidities has recently been developed and validated. Our study aimed to describe and define the risk of patients with CVD and COVID-19 infection.

2. Methods

We performed a meta-analysis in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement (Table 1 of the supplementary data). We carried out a systematic search (using PUBMED, EMBASE, and Cochrane Central Register of Controlled Trials [CENTRAL], and Google Scholar), without language restriction, for papers using the Medical Subject Headings terms “Coronavirus,” “COVID-19,” “Mortality,” “Clinical outcomes” and “Clinical course” up to 25 July 2020. We also reviewed all institutional websites to obtain national reports of coronavirus. The primary outcome was all-cause death. As a result 16 studies that reported clini-
clinical features of patients who died vs survivors were identified: 16 were hospital registries \(^6,7,17,19,20,23-31\) and 2 were national reports (one from China \(^32\) and other from Spain. \(^15\) A total of two hospital registries were not included in the metanalysis, one hospital registry included only patients with CVD, \(^7\) and it was not included in the analysis. The study by Mehra et al. \(^17\) was excluded since results were withdrawn from the journal. National reports from Italy, \(^33\) Germany, \(^34\) UK, \(^35\) Belgium \(^36\) and France \(^37\) did not report the prevalence of CVD in patients who died from COVID. Therefore, analyses were performed using 16 reports (2 national reports and 14 hospital registries). CVD included coronary heart disease, heart failure, and cerebrovascular disease. For the eligible studies, two authors independently abstracted data into a standardized form; discrepancies in data extraction and quality assessment were resolved by discussion or consensus with a third author.

2.1. Statistical analysis

Clinical features and in-hospital mortality were available in all studies. Relative risk reductions and percentage of incidences were used. The study-specific standard errors for the estimated relative risks were used to model the within-study variation. The percentage of variability across studies attributable to heterogeneity beyond chance was estimated using the \(I^2\) statistic. Once heterogeneity was observed and assuming that the study effect sizes were different and that the collected studies represented a random sample from a larger population, all the analyses were performed by a random effects model. Sensitivity analyses were performed for the identification of potential sources of heterogeneity between trials with meta-regression analyses and Harbord test, to assess the small-study effects. \(^33\) All analyses were performed using STATA 14.3 (StataCorp. 2009. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP) software.

3. Results

A total 307,596 patients from 16 reports were included and 46,321 (15.1%) had CVD (Table 1). Mean age was 61.6 (4.3) and 42.5% were males. A total of 25,724 (8.4%) patients died; mortality rates were higher in hospital registries (48.3%; 1926/3988) compared to national reports (8.2%; 20,534/250273). A total of 11,213 (24.2%) patients with CVD died and mortality rates were also higher in hospital registries (48.7%; 988/2028) compared to national reports (23.1%; 10,225/44293). CVD was associated to 4-fold higher risk of mortality (OR, 4.33; 95%CI, 3.16–5.94) (Fig. 1). \(^5,6,19,20,23-30\) Significant heterogeneity was observed between both types of reports and hospital registries reports. The scatter wide distribution in the funnel plot suggested the presence of reporting bias (Fig. 2A) but the small-study effect was excluded by the Harbord test (\(P = .48\)). Meta-regression analysis identified age (\(P < .001\)), fatality rates (\(P = .04\)) and prevalence of CVD and 2 outlier results \(^6,26\) as the main sources of heterogeneity.

We also analyzed the effect of CVD risk factors on mortality. Data from 28,048 patients with diabetes was available. Diabetes was associated to higher mortality risk (OR, 2.41; 95%CI, 1.79–3.26; \(P < .001\)) (Fig. 3). \(^4,6,19,20,23-26,28-31\) Age (\(P < .01\) and data source (\(P = .026\)) were the leading causes of heterogeneity (Fig. 2B). Sensitivity analyses suggested bias in the results of patients with diabetes; the funnel plot was not symmetrical and had a disperse distribution (Fig. 2B) and The Harbord test suggested a small-trial effect (\(P = .01\)). As shown in Fig. 4, \(^5,6,19,20,23-26,28-31\) hypertension was also associated to higher risk of death (OR, 2.60; 95%CI, 2.10–3.21; \(P < .001\)). In contrast, the funnel plot was more symmetrical and had less dispersion (Fig. 2C); moreover, the Harbord test excluded relevant biases or small-study effect (\(P = .39\)).

4. Discussion

The metaanalysis of currently available data suggests that patients with CVD and COVID-19 infection have more than 4-fold higher risk of mortality. Our results may have several clinical implications such as more strict measures for prevention of COVID-19 infection in patients with CVD as well as early and aggressive management of infected patients. \(^18\) The COVID-19 pandemic has irritated in the medical community in terms of diagnosis, containment, and clinical management. \(^15,16,39\) The worldwide spread has increased the urgent need for relevant data; the meritorious reports from China were very illustrative and national reports have progressively increased the knowledge of this unprecedented outbreak.

Four key issues have been highlighted as priority in the field of the COVID-19 outbreak: clarifying the full spectrum of disease, how transmissible it is, identification of the infectious and, defining the risk factors for severe illness or death. \(^15\) CVD was outlined as a risk factor for poorer outcomes, from the first reports, \(^5,7,19,40\) and we conducted this meta-analysis aware of the increasing prevalence of the patients with CVD worldwide. \(^41,42\) Our results suggest that patients with CVD have more than a 4-fold higher risk of death once they get the COVID-19 infection. Clinical variables associated with poor in-hospital outcomes highlighted CVD as one of them. \(^6,7\) The National Health Commission of China designed and validated a risk score to predict severe COVID-19 disease, a combined end-point that included admission to the intensive care unit, invasive ventilation, or death. \(^21\) Our results might reflect that CVD should be taken as a relevant and independent risk factor in COVID-19 patients. We found differences in mortality rates between hospital registries and national reports but the risk associated with CVD was similar in both types of report which might reflect the reliability of national reports and endorse our results. Nonetheless, most clinical series had small sample sizes and were underpowered to assess the actual risk of death associated with CVD in COVID-19 patients. At least 2 hospital series have analyzed the impact of CVD on COVID-19 patients. A report from 99 patients admitted in Northern Italy hospitals, with only 53 patients with CVD, found higher mortality rates in an univariate analysis. \(^20\) A larger report with 522 patients from 2 Spanish hospitals described an independent association of CVD only with the combined end-point of death or respiratory insufficiency. \(^27\) The fact that both series were underpowered to achieve statistically significant results reinforces the need of our metaanalysis.
Table 1 – Summary of the studies included in the metaanalysis.

| First author | Date   | Journal              | Age | males | N total | N dead | N CCVD | CVDDead | NHT | HT dead | NDM | DM dead |
|--------------|--------|----------------------|-----|-------|---------|--------|--------|---------|-----|---------|-----|---------|
| X. Yang      | Feb 2020 | Lancet Resp         | 58.25 | 35   | 52      | 32     | 12     | 10      |     |         |     |         |
| Q. Ruan      | March 2020 | Intensive Care Med | 58.5 | 102  | 150     | 68     | 25     | 20      |     |         |     |         |
| F. Zhou      | March 2020 | Lancet          | 60.5 | 119  | 191     | 54     | 15     | 13      |     |         |     |         |
| MSCyB[19]    | May 29 2020 | website       |     |      | 250273  | 20534  | 43420  | 10133   | 31800  | 24222   | 5532  |
| T. Chen[18]  | March 2020 | BMJ          | 62   | 171  | 274     | 113    | 24     | 17      |     |         |     |         |
| Q. Ruan      | May 14 2020 | Eur Heart J   | 67   | 99   | 26      | 33     | 19     | 29      |     |         |     |         |
| F. Zhou      | April 6 2020 | Int J Cardiol | 65   | 66   | 112     | 14     | 15     | 4       |     |         |     |         |
| C. Wu[24]    | March 2020 | JAMA Inter Med  | 51   | 128  | 201     | 84     | 4      | 39      |     |         |     |         |
| ES. Rosenberg| May 11 2020 | JAMA         | 65   | 858  | 1438    | 292    | 433    | 136     | 816   | 210     | 504  | 134     |
| R. Du[26]    | April 2020 | Eur Resp J      | 57.6 | 97   | 179     | 21     | 29     | 17      |     |         |     |         |
| F. San Roman | Jun 17 2020 | Rev Exp Cardiol | 68   | 522  | 130     | 68     | 43     | 261     |     |         |     |         |
| C. Ferrando[28] | July 9 2020 | Rev Exp Anest Ranim | 64   | 444  | 1004    | 203    | 91     | 38      | 329   | 115     | 151  | 61      |
| G. Grasselli[29] | July 15 2020 | JAMA IM      | 63   | 3188 | 3988    | 1926   | 533    | 342     | 1643  | 962     | 514  | 328     |
| S. Gupta[30] | July 15 2020 | JAMA IM      | 60.5 | 1436 | 2215    | 784    | 288    | 130     | 1322  | 540     | 861  | 352     |
| AM. Borobia[31] | June 4 2020 | J Clin Med   | 61   | 1074 | 2226    | 460    | 429    | 195     | 920   | 318     | 381  | 157     |
| NCP-ERT[32] | March 2020 | China CDC Weekly | 22981 | 44572 | 1023    | 873    | 92     | 2683    | 161   | 1102    | 80   | 6734    |

Total: 61.5 | 30699 | 307596 | 25724 | 46321 | 11213 | 40173 | 2466 | 28048 | 6734

CVD, cardiovascular disease; DM, diabetes mellitus; HT, hypertension; MSCyB, Ministerio de Sanidad, Consumo y Bienestar; NC-ERT, Novel Coronavirus Pneumonia Emergency Response Team.
Mortality associated with CVD

Fig. 1 – Forest plot showing the pooled odds ratio (OR) with 95% confidence intervals (95% CI) of mortality for patients with vs without cardiovascular disease (CVD).

Fig. 2 – Funnel plot for bias analysis in mortality of patients with A, cardiovascular disease; B, diabetes; and C, hypertension.

The mechanisms that could explain the increased risk of death in CVD patients are not fully known. Patients with severe pneumonia, previous CVD, and older age are at higher risk of developing cardiac complications during and after pneumonia. Cardiac injury was detected in 19.7% of patients admitted with COVID-19 symptoms and it was associated with higher risk of in-hospital mortality (HR, 4.26; 95%CI, 1.92–9.49) in a single center study form Wuhan. A recent meta-analysis showed that myocardial injury could be detected in 21% of COVID-19 patients and it was 4 times higher in severe patients. More interestingly, myocardial injury has been reported as an equivalent to previous myocardial infarction in terms of mortality risk in COVID-19 patients. Prolonged fever and pro-inflammatory state are poorly tolerated in patients with CVD and, therefore, acute respiratory distress syndrome and respiratory failure, sepsis, acute cardiac injury, and heart failure, the most severe and common complications during exacerbation of COVID-19, are increased in patients with CVD. Low levels of high-density lipoprotein cholesterol (HDLc) have been clearly related to DM and cardiovascular disease and recent studies have linked low HDLc to higher risk of severe COVID-19.

Patients with CVD have a high prevalence of cardiovascular risk factors and it can also, impair their prognosis. Our results also describe a significant effect of hypertension and diabetes on mortality. The antecedent of hypertension could not be analyzed in the Spanish national report because it was only registered from 18 March 2020. Hypertension and, more especially treatment in angiotensin-receptor blockers or angiotensin receptor antagonist, has received great interest because the COVID-19 virus is known to infect cells by the angiotensin receptor. Nonetheless, there is no solid evidence to withdraw this treatment. Regardless of this treatment debate, our results found a clear increased risk of patients with hypertension or diabetes, that was even higher in national reports. Since significant heterogeneity was observed in our results we conducted sensitivity analyses and excluded the small-studies effect; nonetheless, is difficult to be certain
whether publication bias or studies’ sample size were the most determinant issue because of the presence of substantial heterogeneity. Diabetes is a well-established risk factor for CVD and atherosclerosis and recent metaanalysis described an increased risk of mortality associated with DM (OR, 1.75; 95%CI, 1.31–2.36; P = 0.0002) and our study, with many more studies and patients, fully agrees with those findings.

National reports have been providing rapid and large-scale data from COVID-19 incidence and mortality and, in many cases, other relevant information. National reports have been previously used to analyse the effect of age on mortality in COVID-19 patients and demonstrated that age >50 is the threshold for increased mortality risk. In this new meta-analysis, we used the national COVID-19 report from Spain that included the percentage of patients with CVD and their...
mortality rates as well as many other comorbidities. It should be noted that mortality risk associated with CVD in the Spanish and Chinese reports were identical and it should reflect the reliability of these data sources. Nonetheless, reports included only patients with confirmed infection that were tested before hospital admission and, therefore, they might reflect only the most severe or clinically relevant cases. The criteria for testing, especially in the initial phases of the pandemic, were very different in each region and this was suggested as a key element for the differences in mortality rates.\(^9\) We believe that our results could reinforce the key role of infection prevention in patients with CVD but also, to implement rapid and aggressive diagnosis and treatment in these patients.\(^{16,45}\)

Moreover, second surges of COVID-19 are being reported in several countries or regions and all the evidence from the first surge should be used to improve the management of the pandemic. Patients in the second surge are reported to be younger, with lower burden of overall and specific comorbidities but with longer PCR results.\(^{38}\) This clinical profile might tend to spread the infection and eventually infect patients with CVD. Our meta-analysis highlights that patients with established CVD are at very high-risk of mortality when they get the infection. Evidence supports early and aggressive treatment among patients with CVD because shorter periods of time from the onset of symptoms to the hospital admission have been related to lower mortality rates.\(^7\)

### 4.1. Limitations

Our study has several limitations, mainly derived from the limited evidence available. First of all, reports were based only on patients with laboratory-confirmed infection. Second, official and published data were used and we could not split the effect of different modalities of cardiovascular disease. Third, these findings are probably limited to the most severely ill patients (those that are finally diagnosed due to symptoms). Fourth, the prevalence of obesity was not reported in the publications and, therefore, the impact of excess of weight and its relationship with DM and other clinical features of the metabolic syndrome could not be analyzed. Finally, most national reports do not include the prevalence of CVD or the differential features of patients who died vs survivors. The National Report from Spain represented most patients in the study and in the sub-group of national reports and, therefore, results might not be representative world-wide. We believe that these limitations might have had a minimal effect on results representative and, moreover, might reinforce the need of fast-track publication of reports and clinical registries reporting such valuable data despite the hard conditions.

### 5. Conclusions

In conclusion, the meta-analysis of 305,370 patients highlights that patients with CVD and COVID-19 have more than 4-fold higher risk of mortality, as well as patients with hypertension or diabetes. More clinical and basic research is needed to elucidate the mechanism involved in the cardiovascular manifestations in COVID-19 infected patients and strategies to improve infections and outcomes in CVD patients. Our results should be taken into consideration for future surges of COVID-19 in order to implement preventive measures in patients with CVD.

### What is known about the subject?

- Patients with CVD are at increased risk of infections and have higher mortality rates for infectious diseases.
- Comorbidities, especially age or CVD, have been outlined as a risk factors for poorer outcomes in COVID-19 patients.

### Does it contribute anything new?

- Patients with CVD and COVID-19 have a 4-fold higher risk of death.
- Diabetes or hypertension are associated with twice as high mortality risk in COVID-19.

### Conflicts of interest

Authors have no conflicts of interest related to the results of this study.

### Acknowledgments

Investigators received the support from the Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV CB16/11/00226 – CB16/11/00420).

### Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.rcccl.2020.10.005.

### References

1. Organization WH. Coronavirus disease (COVID-19) outbreak. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 13 Oct 2020.
2. Guan WJ, Ni ZY, Hu Y, et al. China medical treatment expert group for covid-19 clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
3. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069.
4. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–481.
5. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–848.
6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
7. Yudong J, Kai M, Hounquang G, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chin J Cardiol. 2020;48:450–455.
8. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352–2371.
9. Onder G, Rezza G, Brusafermo S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. May 12 2020;323:1775–1776.
10. RENAVE. Informe sobre la situación de COVID-19 en España. Informe COVID-19 nº 9. 2020. Available at: https://www.santepubliquefrance.fr/dossiers/COVID-19-informeCOVID-19-aspn.Accessed 7 May 2020.
11. Prieto-Alhambra D, Ballo E, Coma-Redon E, et al. Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient cases. medRxiv 2020.05.04.20090050; https://doi.org/10.1101/2020.05.04.20090050.
12. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;287:325–344.
13. Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFEY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020. 2020.05.06.20092999.
14. Thomas W, Varley J, Johnston A, et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res. 2020 Jul;191:76–77.
15. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of covid-19 – studies needed. N Engl J Med. 2020;382:1194–1196.
16. Del Rio C, Malani PN. COVID-19 new insights on a rapidly changing epidemic. JAMA. 2020;323:1339–1340.
17. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med. 2020;382:e102. Retraction in: N Engl J Med 2020; 382:2582. doi:10.1056/NEJMec2021225.
18. Restrepo MI, Reyes LF. Pneumonia as a cardiovascular disease. Respiriology. 2018;23:250–259.
19. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.
20. Inciardi RM, Adorno M, Lupi L, et al. Cardiac characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41:1821–1829.
21. Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180:1081–1089.
22. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement, quality of reporting of meta-analyses. Lancet. 1999;354:1986–1900.
23. Deng Q, Hu B, Zhang Y, et al. Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China. Int J Cardiol. 2020;311:116–121.
24. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–943.
25. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323:2493–2502.
26. Du R-H, Liang L-R, Yang G-Q, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55:2000524.
27. San Román JA, Uribarri A, Amat-Santos IJ, Aparisi Á, Catalá P, González-Juanatey JR. La presencia de cardiopatía agrava el pronóstico de los pacientes con COVID-19. Rev Esp Cardiol. 2020;73:773–775.
28. Ferrando C, Mellado-Artigas R, Gea A, et al. Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: a prospective, cohort, multicentre study. Rev Esp Anestesiol Reanim. 2020;67:425–437.
29. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574–1581.
30. Gupta S, Hoyek SS, Wang W, et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020:e203596.
31. Borobia AM, Carcas AJ, Arnalich F, et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. J Clin Med. 2020 Jun 4;9:1733.
32. The Novel Coronavirus Pneumonia Emergency Response Epidemiology T. Vital Surveillance: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) – China. 2020. CCDC Weekly. 2020;2:113-122.
33. Istituto Superiore di Sanità. COVID-19 integrated surveillance: key national data. 2020. Available at: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati. Accessed 25 Jul 2020.
34. Robert Koch-Institut. Aktueller Lage-/Situationsbericht des RKI zu COVID-19. Available at: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.html. Accessed 25 Jul 2020.
35. UK Government. National COVID-19 surveillance reports. 2020. Available at: https://www.gov.uk/government/publications/national-covid-19-surveillance-reports. Accessed 25 Jul 2020.
36. Sciensano. COVID-19 – Situation épidémiologique. 2020. Available from: https://COVID-19.sciensano.be/fr/Covid-19-situation-epidemiologique. Accessed 25 Jul 2020.
37. Santé Publique France. Coronavirus: chiffres clés et évolution de la COVID-19 en France et dans le Monde. 2020. Available at: https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-chiffres-cles-et-evolution-de-la-covid-19-en-france-et-dans-le-monde. Accessed 25 Jul 2020.
38. Everaert BR, Muylle J, Bartholomew Twickler T. Emerging cardiovascular issues during the COVID-19 pandemic. Eur J Clin Invest. 2020;16:e13270; Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
39. Han Y, Zeng H, Jiang H, et al. CSC expert consensus on principles of clinical management of patients with severe emergent cardiovascular diseases during the COVID-19 epidemic. Circulation. 2020;141:810–816.
40. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.
41. Timmis A, Townsend N, Gale CP, et al. European society of cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020;41:12–85.
42. Virani Salim S, Alonso A, Benjamin Emelia J, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141:e139–e596.
43. Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41:1798–1800.
44. Mai F, Del Pinto R, Ferri C. COVID-19 and cardiovascular diseases. J Cardiol. 2020;76:453–458.
45. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810.
46. Gu Z-C, Zhang C, Kong LC, et al. Incidence of myocardial injury in coronavirus disease 2019 (COVID-19): a pooled analysis of 7,579 patients from 53 studies. Cardiovasc Diagn Ther. 2020;10:667–677.
47. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:811–818.
48. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323:1612–1614.
49. Young BE, Ong SWX, Kalimuthu S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323:1488–1494.
50. Cordero A, Moreno-Arribas J, Bertomeu-Gonzalez V, et al. Las concentraciones bajas de colesterol unido a las lipoproteínas de alta densidad se asocian de manera independiente a enfermedad coronaria aguda en pacientes que ingresan por dolor torácico. Rev Esp Cardiol. 2012;65:319–325.
51. Wang G, Zhang Q, Zhao X, et al. Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study. Lipids Health Dis. 2020;19:204.
52. Cordero A, Galve E, Bertomeu-Martinez V, et al. Trends in risk factors and treatments in patients with stable ischemic heart disease seen at cardiology clinics between 2006 and 2014. Rev Esp Cardiol. 2016;69:401–407.
53. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170:1136–1147.
54. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020;382:2441–2448.
55. López-Otero D, López-Pais J, Cacho-Antonio CE, et al. Impact of angiotensin-convertase enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry. Rev Esp Cardiol. 2020, http://dx.doi.org/10.1016/j.recesp.2020.05.018.
56. Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetol. 2020, http://dx.doi.org/10.1007/s00592-020-01546-0.
57. Bonanad C, Garcia-Blas S, Tarazona-Santabalbina F, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020;21:915–918.
58. Vahidy FS, Drews AL, Masud FN, et al. Characteristics and outcomes of COVID-19 patients during initial peak and resurgence in the Houston Metropolitan Area. JAMA. 2020;324:998–1000.